Aspen Neuroscience (ASPE) vs PepGen (PEPG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Aspen Neuroscience is the larger company by market cap ($361.2 million vs $356.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASPE | PEPG |
|---|---|---|
| Share price | $12.42 | $3.78 |
| Market cap | $361.16M | $356.31M |
| 1-day change | +0.24% | -3.82% |
| YTD return | — | -41.94% |
| 1-year return | — | -32.01% |
| EPS (TTM) | $-4.89 | $-0.77 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-89.66M |
| 52-week high | $14.90 | $7.80 |
| 52-week low | $11.20 | $1.31 |
| Distance from 52-week high | -16.64% | -51.54% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +263.76% |
| Average volume | 352.42K | 3.26M |
| Shares outstanding | 29.08M | 94.26M |
| Employees | 120 | 53 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aspen Neuroscience
ASPE stock →Aspen Neuroscience, Inc. develops autologous induced pluripotent stem cell (iPSC)-derived cell replacement therapies for neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 120 employees
About PepGen
PEPG stock →PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 53 employees
ASPE vs PEPG FAQ
Which is bigger, Aspen Neuroscience or PepGen?
Aspen Neuroscience (ASPE) is larger, with a market capitalization of $361.16M compared with $356.31M for PepGen (PEPG).
Are Aspen Neuroscience and PepGen in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.